NYB (NYB Holdings) EBIT: $ Mil (TTM As of Sep. 2025)


What is NYB Holdings EBIT?

NYB Holdings NYB EBIT is $ Mil as of Sep. 2025.

NYB Holdings's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2025 was $1.37 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NYB Holdings's annualized ROC % for the quarter that ended in Sep. 2025 was -1,728.68%. NYB Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 1,254.13%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

NYB Holdings  (NAS:NYB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NYB Holdings's annualized ROC % for the quarter that ended in Sep. 2025 is calculated as:

ROC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=-3.345 * ( 1 - 0% )/( (0.0029999999999992 + 0.384)/ 2 )
=-3.345/0.1935
=-1,728.68 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.305 - 5.214 - ( 0.285 - max(0, 5.217 - 0.305+0.285))
=0.0029999999999992

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.265 - 0.19 - ( 0.889 - max(0, 0.255 - 0.946+0.889))
=0.384

Note: The Operating Income data used here is one times the annual (Sep. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

NYB Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Sep. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.367/( ( (0 + max(-5.194, 0)) + (0.218 + max(-0.151, 0)) )/ 2 )
=1.367/( ( 0 + 0.218 )/ 2 )
=1.367/0.109
=1,254.13 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.02) - (5.214 + 0 + -8.8817841970013E-16)
=-5.194

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.017 + 0 + 0.022) - (0.19 + 0 + 0)
=-0.151

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Sep. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NYB Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2025 )
=/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NYB Holdings EBIT Related Terms

NYB Holdings EBIT Historical Data

* Premium members only.

The historical data trend for NYB Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NYB Holdings EBIT Chart

NYB Holdings Annual Data
Trend Sep24 Sep25
EBIT
-3.52 1.37

NYB Holdings Semi-Annual Data
Sep24 Sep25
EBIT -3.52 1.37

NYB vs : EBIT Comparison

For the Biotechnology subindustry, NYB Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NYB Holdings EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NYB Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NYB Holdings's EV-to-EBIT falls into.


NYB Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $ Mil mean?
NYB Holdings (NYB) has a EBIT of $ Mil as of Sep. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NYB Holdings.
Is NYB Holdings' EBIT too high?
NYB Holdings' current EBIT is $ Mil.
How does NYB Holdings' EBIT compare to ?
NYB Holdings' EBIT of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NYB Holdings. NYB Holdings's current EBIT is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NYB Holdings stock overvalued right now?
NYB Holdings (NYB) has a current EBIT of $ Mil. The current EBIT is $ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For NYB Holdings (NYB), the current EBIT is $ Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NYB Holdings Business Description

Comparable Companies
Address 456 Alexandra Road, No. 04-07, Fragrance Empire Building, Singapore, SGP, 119962
NYB Holdings Ltd, along with its subsidiaries, is a pre-clinical biopharmaceutical company engaged in the research and development of therapeutics and nutraceuticals derived from biodiversity, including tropical medicinal plants with a history of traditional use. It focuses on discovering and developing natural compounds for applications in oncology and other chronic diseases, and also offers a consumer nutraceutical product line.